Live Breaking News & Updates on Polymyalgia rheumatica
Stay updated with breaking news from Polymyalgia rheumatica. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An analysis of Medcare claims data offers clinicians an overview or the effectiveness of sarilumab and tocilizumab in second- and third-line polymyalgia rheumatica treatments relative to conventional immunomodulators, such as methotrexate or azathioprine.
The April 2023 rheumatology month in review highlights recent data regarding physical activity levels among patients with JIA, a link between fibromyalgia and psychiatric disorders, and a feature focused on the treatment of polymyalgia rheumatica.
Despite the recent advancements in the treatment of polymyalgia rheumatica, a need for more research focused on finding non-steroidal treatment options remains.
The interleukin-6 receptor antagonist sarilumab (Kevzara) will be indicated in adults who have had an inadequate response to corticosteroids or could not tolerate a corticosteroid taper.
Relapsing patients treated with the biologic had significantly higher sustained remission and reported better quality of life, compared with the control group, in a randomized controlled trial.
Sparrow Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
As patients wait up to a decade for the diagnosis of life-impacting rheumatic conditions, experts argue that ingrained pressures facing NHS rheumatology services can, and should, be eased with an integrated community care/secondary care approach, rather than a reliance on secondary care alone.
Results indicate that SPI-62 has the potential to mitigate adverse effects of glucocorticoid medications Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing